GleamWall
中文EN

ALLO Allogene Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1737287 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-26.7%
TTM net income YoY22.1%
TTM EPS YoY36.8%
Revenue 3-yr CAGR-91.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,241,813.6%
Net margin-1,170,863.6%
FCF margin-913,609.1%
EBITDA margin-1,179,818.2%

Returns

ROE-55.1%
ROA-43.2%
ROIC (approx.)-57.1%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets23.1%
Debt / equity0.00x
Current ratio8.54x
Interest coverage-1,509.39x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue3,154.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$22,000
R&D expense$150.15M$192.30M
SG&A expense$56.78M$65.20M
Operating income-$209.31M-$273.20M
Interest expense$1.07M$181,000
Pretax income-$190.89M-$257.15M
Income tax$0$443,000
Net income-$190.89M-$257.59M
EBITDA-$196.96M-$259.56M
EPS (basic)-0.87-1.32
EPS (diluted)-0.87-1.32
Dividends declared per share0.000.00
Weighted avg. shares (diluted)220.62M194.81M
Balance sheet
Cash & equivalents$51.69M$85.51M
Short-term investments$198.52M$217.26M
Current assets$257.75M$303.39M
PP&E, net$72.84M$86.06M
Total assets$415.90M$548.71M
Current liabilities$32.51M$35.52M
Total liabilities$123.36M$126.53M
Shareholders' equity$292.54M$422.18M
Shares outstanding229.41M212.21M
Cash flow statement
Operating cash flow-$149.25M-$200.30M
Capital expenditure$386,000$694,000
Free cash flow-$149.63M-$200.99M
Investing cash flow$95.56M$75.69M
Financing cash flow$30.16M$116.67M
Depreciation & amortization$12.36M$13.64M
Stock-based compensation$37.64M$51.74M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.